IRIS
VIGNA, ERNESTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.687
NA - Nord America 2.047
EU - Europa 915
SA - Sud America 761
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 113
OC - Oceania 5
AN - Antartide 1
Totale 6.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.890
SG - Singapore 957
BR - Brasile 566
CN - Cina 530
VN - Vietnam 464
IT - Italia 422
HK - Hong Kong 194
BD - Bangladesh 150
FR - Francia 102
DE - Germania 93
AR - Argentina 64
KR - Corea 64
FI - Finlandia 57
CA - Canada 56
MX - Messico 52
IN - India 44
GB - Regno Unito 42
IQ - Iraq 42
EC - Ecuador 35
ZA - Sudafrica 32
ID - Indonesia 30
UA - Ucraina 30
NL - Olanda 29
PK - Pakistan 29
RU - Federazione Russa 29
CO - Colombia 26
AT - Austria 24
UZ - Uzbekistan 20
TR - Turchia 19
PH - Filippine 17
ES - Italia 16
CL - Cile 15
VE - Venezuela 15
JP - Giappone 14
DZ - Algeria 13
MA - Marocco 13
PL - Polonia 13
PY - Paraguay 13
SA - Arabia Saudita 13
KE - Kenya 11
UY - Uruguay 11
MY - Malesia 10
TN - Tunisia 10
ET - Etiopia 9
JM - Giamaica 9
JO - Giordania 9
NP - Nepal 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
IL - Israele 8
PE - Perù 8
BO - Bolivia 7
CR - Costa Rica 7
KG - Kirghizistan 7
LB - Libano 7
PA - Panama 7
AL - Albania 5
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
CZ - Repubblica Ceca 5
NI - Nicaragua 5
OM - Oman 5
PS - Palestinian Territory 5
SE - Svezia 5
TT - Trinidad e Tobago 5
DO - Repubblica Dominicana 4
HN - Honduras 4
RO - Romania 4
SN - Senegal 4
AU - Australia 3
CH - Svizzera 3
GT - Guatemala 3
KH - Cambogia 3
KZ - Kazakistan 3
NG - Nigeria 3
QA - Qatar 3
RS - Serbia 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
BE - Belgio 2
BN - Brunei Darussalam 2
DK - Danimarca 2
IE - Irlanda 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
LY - Libia 2
MK - Macedonia 2
NO - Norvegia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AQ - Antartide 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
Totale 6.511
Salva come PNG Salva come JPEG
Città #
Singapore 416
San Jose 270
Council Bluffs 262
Dallas 234
Ashburn 220
Hong Kong 192
Ho Chi Minh City 160
Florence 137
Boardman 135
Hefei 103
Beijing 101
Hanoi 99
Seoul 63
Lauterbourg 60
São Paulo 60
New York 48
Shanghai 47
Santa Clara 46
Los Angeles 45
Munich 41
Helsinki 40
Milan 36
Da Nang 24
Rio de Janeiro 24
Rome 23
Haiphong 22
Sesto Fiorentino 22
Montreal 20
Noto 20
Chicago 19
Guangzhou 18
Quito 18
Baghdad 17
Tashkent 17
Brooklyn 15
Mexico City 14
Brasília 13
Phoenix 13
The Dalles 13
Vienna 13
Washington 13
Catania 12
Guayaquil 12
Naples 12
Amsterdam 11
Bari 11
Buffalo 11
Hillsboro 11
Johannesburg 11
Orem 11
Tokyo 11
Frankfurt am Main 10
Lahore 10
Nairobi 10
Addis Ababa 9
Amman 9
Ninh Bình 9
Thái Nguyên 9
Turin 9
Turku 9
Wuhan 9
Atlanta 8
Belo Horizonte 8
Biên Hòa 8
Charlotte 8
Chennai 8
Dhaka 8
Karachi 8
Lappeenranta 8
London 8
Medellín 8
Montevideo 8
Omaha 8
Portland 8
San Francisco 8
Toronto 8
Warsaw 8
Campinas 7
Can Tho 7
Caracas 7
Erbil 7
Fortaleza 7
Hangzhou 7
Kyiv 7
Miami 7
Naaldwijk 7
Nuremberg 7
Ogden 7
Ribeirão Preto 7
Bishkek 6
Bogotá 6
Cape Town 6
Manaus 6
Santiago 6
Boston 5
Bragança Paulista 5
Brescia 5
Curitiba 5
Denver 5
Duhok 5
Totale 3.631
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 182
Vaccination in Multiple Myeloma: Challenges and Strategies 144
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 142
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 132
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 129
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 126
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 126
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 124
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 119
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 118
The role of corticosteroids in the current treatment paradigm for myelofibrosis 118
Momelotinib in myelofibrosis 118
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 114
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 114
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 113
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 113
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 113
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 112
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 111
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 110
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 109
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 107
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 106
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 106
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 100
Iron chelation therapy 100
Belantamab mafodotin in multiple myeloma 100
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 95
Selinexor in multiple myeloma 94
Teclistamab-cqyv in multiple myeloma 94
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 93
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 92
Acalabrutinib in chronic lymphocytic leukemia 92
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 92
Myelodysplastic syndromes with ring sideroblasts 91
Cerebral pheohyphomycosis due to curvularia species 89
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 89
Elotuzumab in multiple myeloma 88
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 86
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 85
Ivosidenib in acute myeloid leukemia 84
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 84
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 83
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 82
Avatrombopag for the Treatment of Immune Thrombocytopenia 80
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 78
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 76
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 72
Glasdegib for the treatment of acute myeloid leukemia 72
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 72
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 72
Zanubrutinib for the treatment of chronic lymphocytic leukemia 71
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 70
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 68
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 67
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 67
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 61
Mosunetuzumab for the treatment of follicular lymphoma 61
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 58
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 57
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 53
Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives 51
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 51
Venetoclax in acute myeloid leukemia 51
Isatuximab in multiple myeloma 50
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 49
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 45
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 35
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 35
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 33
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? 32
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 30
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 26
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 26
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 22
Reshaping multiple myeloma treatment: recent breakthroughs 21
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 21
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 20
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 19
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 19
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 18
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 15
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 13
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 13
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 11
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 9
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 9
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 8
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 7
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 7
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 6
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 6
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 6
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 5
Totale 6.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.756
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202375 2 0 0 2 1 1 32 2 4 5 20 6
2023/2024530 10 17 105 84 49 64 24 17 17 8 19 116
2024/20251.200 45 99 33 62 59 45 24 61 178 124 123 347
2025/20264.409 424 237 407 302 685 315 475 221 356 422 265 300
2026/2027413 324 89 0 0 0 0 0 0 0 0 0 0
Totale 6.643